20:33 , Oct 5, 2018 |  BC Week In Review  |  Company News

Janssen terminates licenses to Aduro cancer therapies

Aduro BioTech Inc. (NASDAQ:ADRO) revealed in an SEC filing that the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) will terminate its licenses for three cancer therapies, effective Dec. 24. A Janssen spokesperson told...
03:11 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

CRS-207: Ph IIb resumed

Aduro said FDA lifted a partial clinical hold on trials evaluating candidates developed using the company's...
23:59 , Nov 21, 2016 |  BC Extra  |  Clinical News

FDA lifts partial hold on Aduro's candidates

Aduro Biotech Inc. (NASDAQ:ADRO) said FDA lifted a partial clinical hold on trials evaluating candidates developed using the company's...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Clinical News

CRS-207: Phase IIb hold

Aduro said FDA placed a partial clinical hold on trials evaluating candidates developed through the company’s live-attenuated double-deleted Listeria monocytogenes (LADD) technology. The hold pauses new patient enrollment but allows patients already treated with LADD-based...
07:00 , Oct 24, 2016 |  BC Extra  |  Clinical News

Partial clinical hold for Aduro's Listeria candidates

Aduro Biotech Inc. (NASDAQ:ADRO) slipped $0.55 to $11.70 on Monday after it said FDA placed a partial clinical hold on trials evaluating candidates developed using the company's Listeria monocytogenes -based immunotherapy construct (LADD) platform. The...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

ADU-741: Phase I started

Johnson & Johnson’s Janssen Biotech Inc. subsidiary began an open-label, dose-escalation, U.S. Phase I trial to evaluate 2 dose levels of IV ADU-741 every 21 days in about 42 patients. Janssen has exclusive, worldwide rights...
23:38 , Jun 11, 2014 |  BC Extra  |  Financial News

Aduro closes $55 million C round

Aduro BioTech Inc. (Berkeley, Calif.) raised an undisclosed amount in a tranched $55 million series C round from new investor Johnson & Johnson Development Corporation (JJDC) and existing investor Morningside Group. Other undisclosed new and...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

Aduro BioTech, J&J deal

Aduro granted Johnson & Johnson's Janssen Biotech Inc. subsidiary exclusive, worldwide rights to prostate cancer products based on Aduro's live-attenuated double-deleted Listeria monocytogenes (LADD) immunotherapy platform. The lead compound under the deal is Aduro's ADU-741...
00:53 , May 30, 2014 |  BC Extra  |  Company News

Aduro licenses immunotherapy products to Janssen

Aduro BioTech Inc. (Berkeley, Calif.) granted the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to prostate cancer products based on Aduro's live-attenuated double-deleted Listeria monocytogenes (LADD) immunotherapy platform. The lead...